Education
About Us
Working with TipRanks
Follow Us
Aspire Biopharma Holdings (ASBP)
NASDAQ:ASBP
RESEARCH TOOLSreports
Total Valuation
Aspire Biopharma Holdings has a market cap or net worth of ―. The enterprise value is ―.
Market Cap―
Enterprise Value―
Share Statistics
Aspire Biopharma Holdings has 49,525,970 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding49,525,970
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Aspire Biopharma Holdings’s return on equity (ROE) is 0.74 and return on invested capital (ROIC) is 282.23%.
Return on Equity (ROE)0.74
Return on Assets (ROA)-7.78
Return on Invested Capital (ROIC)282.23%
Return on Capital Employed (ROCE)0.74
Revenue Per Employee0.00
Profits Per Employee2.23M
Employee Count2
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Aspire Biopharma Holdings is -1.47K. Aspire Biopharma Holdings’s PEG ratio is 0.61.
PE Ratio-1.47K
PS Ratio0.00
PB Ratio-31.54
Price to Fair Value-1.08K
Price to FCF-58.08
Price to Operating Cash Flow-62.67
PEG Ratio0.61
Income Statement
In the last 12 months, Aspire Biopharma Holdings had revenue of 0.00 and earned 4.46M in profits. Earnings per share was 0.23.
Revenue0.00
Gross Profit0.00
Operating Income-1.34M
Pretax Income4.46M
Net Income4.46M
EBITDA5.80M
Earnings Per Share (EPS)0.23
Cash Flow
In the last 12 months, operating cash flow was -900.88K and capital expenditures -18.82K, giving a free cash flow of -862.63K billion.
Operating Cash Flow-900.88K
Free Cash Flow-862.63K
Free Cash Flow per Share-0.02
Dividends & Yields
Aspire Biopharma Holdings pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.62
52-Week Price Change-96.66%
50-Day Moving Average0.45
200-Day Moving Average7.66
Relative Strength Index (RSI)46.35
Average Volume (3m)25.09M
Important Dates
Aspire Biopharma Holdings upcoming earnings date is ―, TBA Not Confirmed.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Aspire Biopharma Holdings as a current ratio of 0.09, with Debt / Equity ratio of -106.43%
Current Ratio0.09
Quick Ratio0.09
Debt to Market Cap<0.01
Net Debt to EBITDA0.00
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Aspire Biopharma Holdings has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate>-0.01
Enterprise Valuation
Aspire Biopharma Holdings EV to EBITDA ratio is 0.00, with an EV/FCF ratio of 47.51K.
EV to Sales0.00
EV to EBITDA0.00
EV to Free Cash Flow47.51K
EV to Operating Cash Flow6.08K
Balance Sheet
Aspire Biopharma Holdings has $16.54K in cash and marketable securities with $853.11K in debt, giving a net cash position of $836.57K billion.
Cash & Marketable Securities$16.54K
Total Debt$853.11K
Net Cash$836.57K
Net Cash Per Share$0.02
Tangible Book Value Per Share-$0.01
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Aspire Biopharma Holdings is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―